

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

VOLUNTARY ANNOUNCEMENT INCREASE IN SHAREHOLDING BY DIRECTORS AND CONTROLLING SHAREHOLDERS

This is a voluntary announcement made by Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company was informed by Ms. Wang Ye (“**Ms. Wang**”), an executive Director and a controlling shareholder of the Company, that on 22 September 2020, 23 September 2020 and 24 September 2020, Ms. Wang acquired a total of 638,000 ordinary shares of the Company (the “**Share(s)**”) on the market for an aggregate consideration of approximately HK\$7,553,560 (representing an average price of approximately HK\$11.839 per Share) (“**Ms. Wang’s Acquisition**”).

The Board was also informed by Dr. Wang Luquan (“**Dr. Wang**”), a non-executive Director and a controlling shareholder of the Company, that on 22 September 2020, a close associate of Dr. Wang acquired a total of 638,000 Shares on the market for an aggregate consideration of approximately HK\$7,614,720 (representing an average price of approximately HK\$11.935 per Share) (“**Dr. Wang’s Acquisition**”).

The Board was also informed by Mr. Meng Jiange (“**Mr. Meng**”), an executive Director of the Company, that on 22 September 2020, 23 September 2020 and 24 September 2020, Mr. Meng acquired a total of 120,000 Shares on the market for an aggregate consideration of approximately HK\$1,416,200 (representing an average price of approximately HK\$11.802 per Share) (“**Mr. Meng’s Acquisition**”, together with the Ms. Wang’s Acquisition and Dr. Wang’s Acquisition, the “**Acquisitions**”).

Ms. Wang and Dr. Wang are parties acting in concert with Dr. Zhang Fangliang, a non-executive director and chairman of the Company. Immediately following the Ms. Wang’s Acquisition and Dr. Wang’s Acquisition, each of Ms. Wang and Dr. Wang is deemed to be interested in 944,684,581 Shares, representing approximately 49.15% of the total issued share capital of the Company as at the date of this announcement.

Immediately following the Mr. Meng's Acquisition, Mr. Meng is interested in 2,825,037 Shares, representing approximately 0.15% of the total issued share capital of the Company as at the date of this announcement.

The Acquisitions were conducted in compliance with applicable laws, rules and regulations, including the Model Code for Securities Transactions by Directors of Listed Issuers in Appendix 10 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited adopted by the Company.

The Company believes that the Acquisitions fully demonstrate the confidence of Ms. Wang, Dr. Wang, and Mr. Meng in the overall development prospects and growth potentials of the Group.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Wang Ye
Executive Director

Hong Kong, 24 September 2020

As at the date of this announcement, the executive Directors are Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Zhang Fangliang, Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Mr. Pan Jiuan.

* *For identification purposes only*